# OPZELURA (opzelura) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/opzelura

> The FDA approved OPZELURA (opzelura), sponsored by INCYTE CORP (INCY), on Jul 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | OPZELURA (opzelura) |
| Codes |  |
| Sponsor | INCYTE CORP (INCY) https://sec-api.dev/companies/incy/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul 2022: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-10, last confirmed 2025-07-29.
- SEC Form 10-Q (accession 0000879169-25-000103): "In July 2022, we announced that the FDA approved OPZELURA for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older." https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm
- SEC Form 10-Q (accession 0000879169-25-000056): "In July 2022, we announced that the FDA approved OPZELURA for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older." https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm
- SEC Form 10-K (accession 0001628280-25-004633): "In July 2022, we announced that the FDA approved OPZELURA for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older." https://www.sec.gov/Archives/edgar/data/879169/000162828025004633/incy-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/opzelura.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OPZELURA (opzelura) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/opzelura

```bibtex
@misc{secapidev_pdufa_opzelura_20261116,
  title        = {OPZELURA (opzelura) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/opzelura}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_opzelura_20261116","title":"OPZELURA (opzelura) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/opzelura","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
